U. S. China links to health and medical products, assessing Market Opportunities Economic Health and National Security risks of these relationships. We will start with Benjamin Shobert at a senior associate for interNational Health, the National Hero of asian research. Mr. Shobert is the director of strategy for Health Business strategy at microsoft where he lead engagements with national governments, providers and the biotech community. Next we will hear from Katherine Eban an investigative journalist for Fortune Magazine contributor and arnie Andrew Carnegie fellow. Ms. Ebans book bottle of lies reveals fraud and i are conditions in the overseas manufacturing plants with the majority of her low caste low cost where medicines made. Our third panelist is Yanzhong Huang professor and director of Global Health studies at seaton hall university. Dr. Huang is also a senior in Foreign Relations where he directs the health and governments around table series encoder asked the Global Governan
China s sudden shift away from its strict COVID-19 containment measures took many U.S. analysts by surprise, sparking expectations that Beijing s apparent policy response to popular unrest would allow for a return to pre-pandemic normalcy and possibly warmer Sino-U.S. ties.
The state of healthcare in China is in many ways better than it was in the era of the barefoot doctors, with average life expectancy in the country now trailing the United States by only three years and morbidity rates far lower too. But while even the most cutting-edge medical services are available in first-tier cities for a price, China’s transition to a market economy has left many in the lurch, with out-of-pocket healthcare costs soaring even as the government rolls out more comprehensive health insurance support. How have the new healthcare system reforms inaugurated in 2009 worked out so far?